Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Telos Capital Management Inc.

Telos Capital Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 3.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,174 shares of the pharmaceutical company's stock after buying an additional 547 shares during the quarter. Telos Capital Management Inc.'s holdings in Vertex Pharmaceuticals were worth $8,811,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Alps Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 67.1% in the 1st quarter. Alps Advisors Inc. now owns 1,317 shares of the pharmaceutical company's stock valued at $639,000 after purchasing an additional 529 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Vertex Pharmaceuticals by 11.8% in the 1st quarter. Allworth Financial LP now owns 1,946 shares of the pharmaceutical company's stock valued at $958,000 after purchasing an additional 205 shares in the last quarter. Alpine Woods Capital Investors LLC raised its stake in Vertex Pharmaceuticals by 139.7% during the 1st quarter. Alpine Woods Capital Investors LLC now owns 5,585 shares of the pharmaceutical company's stock worth $2,708,000 after acquiring an additional 3,255 shares in the last quarter. Leavell Investment Management Inc. raised its stake in Vertex Pharmaceuticals by 22.5% during the 1st quarter. Leavell Investment Management Inc. now owns 7,734 shares of the pharmaceutical company's stock worth $3,750,000 after acquiring an additional 1,423 shares in the last quarter. Finally, Quotient Wealth Partners LLC raised its stake in Vertex Pharmaceuticals by 15.2% during the 1st quarter. Quotient Wealth Partners LLC now owns 1,130 shares of the pharmaceutical company's stock worth $548,000 after acquiring an additional 149 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Down 2.2%

VRTX traded down $10.68 during trading on Friday, hitting $468.85. 892,738 shares of the company's stock were exchanged, compared to its average volume of 1,426,652. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a 50 day moving average price of $447.71 and a 200 day moving average price of $460.40. The firm has a market cap of $120.40 billion, a P/E ratio of -119.60 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. Vertex Pharmaceuticals's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $4.76 EPS. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research reports. Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Leerink Partners reissued a "market perform" rating and set a $503.00 price objective (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Scotiabank lowered their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research report on Tuesday, May 6th. Finally, Wolfe Research downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a report on Wednesday, May 7th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $511.62.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.